Navigation Links
Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
Date:10/14/2008

Drug User Fee Act (PDUFA) goal date will be 16 January 2009. Arpida submitted a Marketing Authorisation Application for intravenous iclaprim with EMEA in July 2008. EMEA notified that it had accepted the MAA for review in August 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In May 2008, Arpida announced the enrolment of the first patients in a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Results of "first-in-man" studies with AR-709 were published in March 2007.

An additional antibacterial compound, AR-2474, has demonstrated in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assu
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
2. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
3. Arpida Provides Further Comments on the Pivotal Phase III Trials
4. Arpida Invited to Present Data on Iclaprim at Scientific Conference
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
9. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
10. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
11. Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... 15, 2009 special dividend payment of $1.67 per share ... December 1, 2009. With this payment, distributions to ... $2.67 per share. In January 2010, the Company ... of the Company,s 2009 cash distributions and the allocation ...
(Date:12/15/2009)... BALTIMORE, Dec. 15 Champions Biotechnology, ... engaged in the development of advanced preclinical platforms ... of oncology drugs, today announced its financial results ... 2009. Full details of Company,s financial results ... www.championsbiotechnology.com . ,, Total revenues for the ...
(Date:12/15/2009)... KV Pharmaceutical Company ( KVa/KVb) today announced that ... notice (the "Notice") executed by the Marc S. Hermelin ... requesting that the Board of Directors of the Company ... by written consent relating to the proposed appointment of ... from Ronald J. Kanterman,s departure (the "Director Appointment"). ,, ...
Breaking Medicine Technology:PDL BioPharma Completes December 15 Special Dividend Payment 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7Proprietary EDM Machining Technology Boosts Speed and Accuracy for Medical Components 61534 1Proprietary EDM Machining Technology Boosts Speed and Accuracy for Medical Components 61534 2ASAP Systems Releases Latest Version of their Passport Inventory and Asset Tracking Software with New Security Features and Administrative Tools 61529 1ASAP Systems Releases Latest Version of their Passport Inventory and Asset Tracking Software with New Security Features and Administrative Tools 61529 2Smoking Causes Blindness 61525 1Smoking Causes Blindness 61525 2
(Date:12/15/2009)... strength than needed for protection, CDC says, , , TUESDAY, ... of H1N1 swine flu vaccine have been recalled by ... potency, federal health officials said Tuesday. , According to ... company,s routine testing of the vaccine for children aged ... batches had lower than required potency levels. "This means ...
(Date:12/15/2009)... Calif., Dec. 15 ... in the pharmaceutical and bio-tech research market ... Research). Over the past 11 years CMR ... Physicians Consulting Network (PCN®), which now includes ... covering both primary care and hard-to-reach specialties. ...
(Date:12/15/2009)... --The following are the remarks by Lanny ... division, at the Medicare Fraud Strike Force press ... you for the enormous effort everyone at HHS ... Together, our Departments have and will continue to ... tremendous progress in fighting Medicare fraud in South ...
(Date:12/15/2009)... activity is known to reduce depression and fatigue in ... that this effect stems from an individual,s sense of ... ability to achieve certain physical goals. , The ... , "We base our arguments on fatigue being a ... kinesiology and community health at the University of Illinois ...
(Date:12/15/2009)... to recognize symptoms will call for help, experts say ... could be reduced by teaching children how to spot ... 911 immediately, a new study shows. , Emergency medical ... can limit the extent of brain damage and lead ... Stroke (KIDS) project included 515 sixth graders in Texas ...
Breaking Medicine News(10 mins):Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3Health News:Mastery of physical goals lessens disease-related depression and fatigue 2Health News:Boosting Kids' Stroke IQ May Save Lives 2
... benefits of Olive Oil has been argued by dieticians ... it may preserve the cardiovascular health as well owing ... ,Researchers from Spain compared the effects of consuming ... related compounds. The high concentration of phenolic compounds normally ...
... countries is in the threat of ban on their export ... seafood from Asian countries had the banned chemical Malachite green ... Canadian Food Inspection Agency should follow strict stringent rules and ... country for the presence of Malachite green and its byproducts. ...
... A new outbreak of H5N1 avian influenza has been ... China. ,This bird flu outbreak is the 23rd in ... 246 birds died in Inner Mongolia's Zalantun city last ... have culled 16,567 birds at poultry farms within three,km ...
... a deadly potion was brought home in a very uncomfortable ... of the greatest footballers' died in London yesterday. // ... own liver failed in the aftermath of his boozing exploits. ... world over, mostly male, suffer from alcohol-related liver disease each ...
... been detected throughout the Indonesian capital, Jakarta, with the country's ... our research, the virus has spread all over the city.' ... Indonesia's 30 provinces and has killed seven people., ,Indonesian ... be expected, saying that the virus has spread to at ...
... Insulin like-Growth Factor (IGF-1) is required for both ... secretion of IGF is mediated by the pituitary ... and is associated with metabolic abnormalities including insulin ... drugs helps in production of IGF-1 in children’s ...
Other Medicine News:Health News:Bird Flu Alarm In Indonesia 2
... The Self-Cath Closed System is ... a method for safe, simple catheterization ... urinary tract infections. It includes ... The new EasyOff tear tab ...
... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
Medicine Products: